Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma

Update Il y a 4 ans
Reference: NCT01912872

Woman and Man

  • | Country :
  • Mexico
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess efficacy and safety of omalizumab treatment during 12 months in order to reduce the use of inhaled corticosteroid (ICS) in pediatric and adult patients with severe IgE-mediated asthma inadequately controlled with high doses of corticosteroids.


Inclusion criteria

  • Severe IgE-mediated Asthma

Links